Third Wave's Shares Rise 11 Percent Following European OK for HPV Test | GenomeWeb
NEW YORK (GenomeWeb News) – Shares of Third Wave Technologies rose nearly 11 percent yesterday after the firm said that European regulatory authorities granted the CE Mark for the firm’s molecular diagnostic test for human papillomavirus.
The clearance from the European Union gives the company the green light to sell the test, which detects 14 high-risk types of HPV and is used in screening for cervical cancer, in EU member nations and in other nations that recognize the CE mark.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.